Temporal differential effects of proinflammatory cytokines on osteoclastogenesis

International Journal of Molecular Medicine

Volumn 31, Issue 4, 2013, Pages 769-777

  Moon, Su Jin ^a   Ahn, Inhye E ^b   Jung, Hyerin ^a   Yi, Hyoju ^a   Kim, Juryun ^a   Kim, Youngkyun ^a   Kwok, Seung Ki ^a   Park, Kyung Su ^a   Min, Jun Ki ^a   Park, Sung Hwan ^a   Kim, Ho Youn ^a   Ju, Ji Hyeon ^a  

^a The Catholic University of Korea   (South Korea)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Inflammation; Interleukin 1 ; Interleukin 6; Nuclear factor B; Osteoclast; Receptor activator nuclear factor B ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CONTROLLED STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL;

ANIMALS; BONE MARROW CELLS; CELL SURVIVAL; CYTOKINES; LUCIFERASES; MACROPHAGES; MALE; MICE; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 84875261495     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1269     Document Type: Article

References (31)

1. Sato K and Takayanagi H: Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 18: 419-426, 2006.
2. Schett G: Osteoimmunology in rheumatic diseases. Arthritis Res Ther 11: 210, 2009.
3. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E and Goldring SR: Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43: 250-258, 2000.
4. Martin TJ and Ng KW: Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity. J Cell Biochem 56: 357-366, 1994.
5. + dendritic cells. J Immunol 177: 3314-3326, 2006.
6. Choi Y, Woo KM, Ko SH, Lee YJ, Park SJ, Kim HM and Kwon BS: Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 31: 2179-2188, 2001.
7. Xing L, Schwarz EM and Boyce BF: Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 208: 19-29, 2005.
8. Cappellen D, Luong-Nguyen NH, Bongiovanni S, Grenet O, Wanke C and Susa M: Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 277: 21971-21982, 2002.
9. Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, Min SY, Cho YG, Park SH and Kim HY: Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 110: 54-64, 2007.
10. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ and Gillespie MT: Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 265: 144-150, 1999.
11. Pettit AR, Walsh NC, Manning C, Goldring SR and Gravallese EM: RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 45: 1068-1076, 2006.
12. Schett G, Hayer S, Zwerina J, Redlich K and Smolen JS: Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1: 47-54, 2005.
13. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A and Abu-Amer Y: Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276: 563-568, 2001.
14. O' Gradaigh D, Ireland D, Bord S and Compston JE: Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 63: 354-359, 2004.
15. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, etal: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90: 11924-11928, 1993.
16. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA and van den Berg WB: IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 170: 2655-2662, 2003.
17. + T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 181: 1507-1518, 2008.
18. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ and Suda T: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275-286, 2000.
19. Kim JH, Jin HM, Kim K, Song I, Youn BU, Matsuo K and Kim N: The mechanism of osteoclast differentiation induced by IL-1. J Immunol 183: 1862-1870, 2009.
20. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y and Athanasou NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1-7, 2003.
21. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP and Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488, 2000.
22. Akatsu T, Takahashi N, Debari K, Morita I, Murota S, Nagata N, Takatani O and Suda T: Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3′,5′-monophosphate in mouse bone marrow cell cultures. J Bone Miner Res 4: 29-35, 1989.
23. Baker-LePain JC, Nakamura MC and Lane NE: Effects of inflammation on bone: an update. Curr Opin Rheumatol 23: 389-395, 2011.
24. Brennan FM and McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118: 3537-3545, 2008.
25. Walsh NC, Crotti TN, Goldring SR and Gravallese EM: Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208: 228-251, 2005.
26. Tracey D, Klareskog L, Sasso EH, Salfeld JG and Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117: 244-279, 2008.
27. Furst DE: Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26: 1960-1975, 2004.
28. Gabay C, Lamacchia C and Palmer G: IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6: 232-241, 2010.
29. Fonseca JE, Santos MJ, Canhao H and Choy E: Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8: 538-542, 2009.
30. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N and Kotake S: IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9: R96, 2007.
31. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, Boots AM, Gram H, Joosten LA and van den Berg WB: Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167: 141-149, 2005.